Cancer Genetics (NASDAQ:CGIX) Stock Price Down 7.1%
Shares of Cancer Genetics Inc (NASDAQ:CGIX) traded down 7.1% during mid-day trading on Tuesday . The company traded as low as $0.13 and last traded at $0.13, 2,007,160 shares changed hands during mid-day trading. A decline of 1% from the average session volume of 2,026,844 shares. The stock had previously closed at $0.14.
The company has a debt-to-equity ratio of 0.24, a current ratio of 0.36 and a quick ratio of 0.36. The company’s 50-day moving average is $0.16.
Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings results on Monday, May 20th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $6.84 million during the quarter. Cancer Genetics had a negative net margin of 77.28% and a negative return on equity of 175.72%.
Cancer Genetics Company Profile (NASDAQ:CGIX)
Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Further Reading: 52-Week High/Low
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.